These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2647913)

  • 21. Low-dose cyclophosphamide and low-dose interleukin-2 for malignant melanoma.
    Mitchell MS; Kempf RA; Harel W; Shau H; Boswell WD; Lind S; Dean G; Moore J; Bradley EC
    Bull N Y Acad Med; 1989 Jan; 65(1):128-44. PubMed ID: 2532554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
    Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histological evidence of natural killer cell aggregation against malignant melanoma induced by adoptive immunotherapy with lymphokine-activated killer cells.
    Yamamura T; Fujitani Y; Kawauchi T; Wada E; Kobayashi Y; Yoshikawa K; Ogawa H; Sugiyama H; Ohsawa M; Aozasa K
    J Pathol; 1989 Mar; 157(3):201-4. PubMed ID: 2784498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Adoptive immunotherapy with interleukin 2. Initial results of a pilot study in 6 cancer patients].
    Sculier JP; Bron D; Delforge A; Body JJ; Verboven N; Frühling J; Stryckmans P; Klastersky J
    Presse Med; 1989 Jun; 18(23):1155-8. PubMed ID: 2525748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma.
    Thompson JA; Bianco JA; Benyunes MC; Neubauer MA; Slattery JT; Fefer A
    Cancer Res; 1994 Jul; 54(13):3436-41. PubMed ID: 8012963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases.
    Keilholz U; Scheibenbogen C; Brado M; Georgi P; Maclachlan D; Brado B; Hunstein W
    Eur J Cancer; 1994; 30A(1):103-5. PubMed ID: 8142149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study.
    Stoter G; Shiloni E; Aamdal S; Cleton FJ; Iacobelli S; Bijman JT; Palmer P; Franks CR; Rodenhuis S
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S41-3. PubMed ID: 2697578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulmonary toxicity of recombinant interleukin-2 plus lymphokine-activated killer cell therapy.
    Villani F; Galimberti M; Rizzi M; Manzi R
    Eur Respir J; 1993 Jun; 6(6):828-33. PubMed ID: 8339802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.
    Parkinson DR; Fisher RI; Rayner AA; Paietta E; Margolin KA; Weiss GR; Mier JW; Sznol M; Gaynor ER; Bar MH
    J Clin Oncol; 1990 Oct; 8(10):1630-6. PubMed ID: 2213100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of combined levamisole with recombinant interleukin-2 in patients with advanced malignant melanoma.
    Creagan ET; Rowland KM; Suman VJ; Kardinal CG; Marschke RF; Marks RS; Maples WJ
    Am J Clin Oncol; 1997 Oct; 20(5):490-2. PubMed ID: 9345334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.
    Gibbs P; Iannucci A; Becker M; Allen J; O'Driscoll M; McDowell K; Williams P; Rosse P; Murphy J; Gonzalez R
    Melanoma Res; 2000 Apr; 10(2):171-9. PubMed ID: 10803718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study.
    Shiloni E; Pouillart P; Janssens J; Splinter T; Di Peri T; Symann M; Roest GJ; Palmer PA; Franks CR
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S45-9. PubMed ID: 2697579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors.
    Allison MA; Jones SE; McGuffey P
    J Clin Oncol; 1989 Jan; 7(1):75-80. PubMed ID: 2783339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.
    Topalian SL; Solomon D; Avis FP; Chang AE; Freerksen DL; Linehan WM; Lotze MT; Robertson CN; Seipp CA; Simon P
    J Clin Oncol; 1988 May; 6(5):839-53. PubMed ID: 3259261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of lymphokine-activated killer cells in strain 2 guinea pigs with human interleukin-2.
    Zwilling BS; Aldrich WA; Rinehart JJ
    Cancer Res; 1986 Nov; 46(11):5667-70. PubMed ID: 3489527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Continuous infusion interleukin-2 and intravenous famotidine in metastatic melanoma.
    Quan WD; Milligan KS; Quan FM; Cuenca RE; Khan N; Liles DK; Walker PR
    Cancer Biother Radiopharm; 2006 Dec; 21(6):607-12. PubMed ID: 17257076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity.
    Steis RG; Urba WJ; VanderMolen LA; Bookman MA; Smith JW; Clark JW; Miller RL; Crum ED; Beckner SK; McKnight JE
    J Clin Oncol; 1990 Oct; 8(10):1618-29. PubMed ID: 2213099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma.
    Safwat A; Schmidt H; Bastholt L; Fode K; Larsen S; Aggerholm N; von der Maase H
    Radiother Oncol; 2005 Nov; 77(2):143-7. PubMed ID: 16216360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.
    Soiffer RJ; Chapman PB; Murray C; Williams L; Unger P; Collins H; Houghton AN; Ritz J
    Clin Cancer Res; 1997 Jan; 3(1):17-24. PubMed ID: 9815532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
    Lafreniere R; Rosenberg SA
    Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.